Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

Trial ID or NCT#

NCT01085630

Status

not recruiting iconNOT RECRUITING

Purpose

RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well pemetrexed disodium or observation works in treating patients with malignant pleural mesothelioma without progressive disease after first-line chemotherapy.

Official Title

Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients With Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy

Eligibility Criteria

Ages Eligible for Study: Older than 18
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Histologically confirmed malignant pleural mesothelioma meeting 1 of the following cell types:
  2. * Epithelial * Sarcomatoid * Mixed type
  3. * Histologically documented malignant pleural mesothelioma, epithelial, sarcomatoid or mixed type, not amenable to surgical resection * Prior treatment* Currently receiving first-line treatment with pemetrexed + platinum; patients are to be registered to Cancer and Leukemia Group B (CALGB) 30901 no later than the last day of cycle 4 of first line therapy* Prior intracavitary cytotoxic or sclerosing therapy (including bleomycin) are acceptable; prior intrapleural cytotoxic chemotherapy will not be considered systemic chemotherapy* Prior surgical treatment is allowed* Prior radiation therapy is allowed
  4. * Non-pregnant and non-nursing; women of child bearing potential and men must agree to use an appropriate method of birth control throughout their participation in this study; appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives (Norplant), or double barrier methods (diaphragm plus condom) * RANDOMIZATION ELIGIBILITY CRITERIA * Patients with complete response, partial response, or stable disease following 4, 5 or 6 cycles of first-line chemotherapy with pemetrexed AND either cisplatin or carboplatin; a maximum of 6 cycles of chemotherapy may have been given * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Granulocytes \>= 1,500/ul * Platelet count \>= 100,000/ul * Total bilirubin =\< 1.5 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) =\< 2 x ULN * Calculated creatinine clearance \>= 45 ml/min* Disease not amenable to surgery* Must be enrolled on imaging protocol CALGB-580903* Complete response, partial response, or stable disease after completion of 4 courses of first-line chemotherapy comprising pemetrexed disodium AND cisplatin or carboplatin
  5. * Study therapy will begin within 9 weeks following day 1 of cycle 4 of first-line treatment* No clinically significant pleural or peritoneal effusions that cannot be adequately managed by drainage before or during pemetrexed disodium
    1. PATIENT CHARACTERISTICS:
  7. * ECOG performance status of 0-1* Life expectancy ≥ 12 weeks* Granulocytes ≥ 1,500/μL* Platelet count ≥ 100,000/μL* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)* AST ≤ 2 times ULN* Creatinine clearance ≥ 45 mL/min* Not pregnant or nursing* Negative pregnancy test* Fertile patients must use effective contraception* No psychiatric illness that would prevent the patient from giving informed consent* No second malignancy except non-melanoma skin cancer or carcinoma in situ of the cervix unless curatively treated with no evidence of active disease for ≥ 5 years* No medical conditions that, in the opinion of the treating physician, would make study treatment unreasonably hazardous for the patient including, but not limited to, the following:
  8. * Ongoing or active infection such as HIV positivity * Inability to take oral medications * Psychiatric illness/social situations that would limit compliance with study requirements
    1. PRIOR CONCURRENT THERAPY:
  10. * See Disease Characteristics* Prior intracavitary cytotoxic or sclerosing therapy (including bleomycin) allowed
  11. * Prior intrapleural cytotoxic chemotherapy not considered systemic chemotherapy* Prior surgery allowed* Prior radiotherapy allowed
  12. * No concurrent palliative radiotherapy* No concurrent hormones or other chemotherapeutic agents except for the following:
  13. * Steroids for adrenal failure * Hormones for nondisease-related conditions (e.g., insulin for diabetes) * Intermittent use of dexamethasone as an antiemetic or premedication for pemetrexed disodium
Exclusion Criteria:
View All Criteria
Show Less

Investigator(s)

Joel Neal, MD, PhD
Joel Neal, MD, PhD
Medical oncologist, Thoracic specialist
Professor of Medicine (Oncology)
Heather Wakelee
Heather Wakelee
Medical oncologist, Thoracic specialist
Winston Chen and Phyllis Huang Professor

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061

View on ClinicalTrials.gov